Praluent, the Next Expensive "Game Changer," Blockbuster," "New Hope," - But Not Yet Shown to Benefit Patients

Here we go again.  The same month that it approved Entresto (look here ), the US Food and Drug Administration approved a new PCSK9 inhibitor...

Entresto: Blockbuster, or Just Over Hyped? - Whatever, It Will Cost $4500 a Year

The newest drug for congestive heart failure, Entresto, a fixed combination of valsartan and sacubitril, has just hit the market at an eleva...

Bill Clinton, Paid to Speak to Biotech Conference, Extolled $1000 Pill to Prevent "Liver Rot," Despite Lack of Evidence that It Does

What were they thinking? Former President Clinton Talkes to Pharma and Biotech Executives In mid June, 2015, the Philadelphia Inquirer repor...

Why is the New England Journal of Medicine Scolding "Pharmascolds"? I, a normally quiet blogger on this site, was disquieted by wh...

Promoting Amphetamines for Over-Eating - What Could Possibly Go Wrong?

Every day seems to bring the latest breathlessly touted innovation in modern health care.  The endless hawking of new health care wonders is...

Logical Fallacies in Defense of Aggresive Screening for and Treatment of Hepatitis C

And the hepatitis C follies continue... As we have frequently written, most recently last week , the hepatitis C screening and treatment ba...

The Fashion Challenges of the Emperor of Hepatitis C Treatment - Now in the BMJ, but Who Will Notice?

As we wrote, most recently last week, the hepatitis C screening and treatment bandwagon keeps rolling along.  There is constant public argu...